Prevention of Post-Traumatic Stress Disorder After Trauma: Current Evidence and Future Directions

Wei Qi1 · Martin Gevonden1 · Arieh Shalev1

Published online: 23 January 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract  Post-traumatic stress disorder (PTSD) is a frequent, tenacious, and disabling consequence of traumatic events. The disorder’s identifiable onset and early symptoms provide opportunities for early detection and prevention. Empirical findings and theoretical models have outlined specific risk factors and pathogenic processes leading to PTSD. Controlled studies have shown that theory-driven preventive interventions, such as cognitive behavioral therapy (CBT), or stress hormone-targeted pharmacological interventions, are efficacious in selected samples of survivors. However, the effectiveness of early clinical interventions remains unknown, and results obtained in aggregates (large groups) overlook individual heterogeneity in PTSD pathogenesis. We review current evidence of PTSD prevention and outline the need to improve the disorder’s early detection and intervention in individual-specific paths to chronic PTSD.

Keywords  Post-traumatic stress disorder · Prevention · Early treatment · Cognitive behavioral therapy · Pharmacotherapy · Targeted intervention

Introduction  The psychological effects of wars, disasters, terror, and other traumatic life events, can be deleterious and far-reaching. Post-traumatic stress disorder (PTSD) is the most widely researched consequence of traumatic events and as such epitomizes post-traumatic psychopathology. The clinical features comprising PTSD are event-related symptoms (intrusive recall of aspects of the event, avoidance of reminders, hyper-vigilance) along with dysphoria, hyperarousal, or anhedonia. PTSD is a prevalent consequence of both mundane traumatic events, such as road traffic accidents (7 to 26 %) [1] and protracted exposures to threat, such as wars (8 to 12.7 % among warzone-exposed US military personnel) [2]. PTSD may persist, unremitting, for years and decades in a subset of trauma-exposed survivors. The second wave of data collection (2013) of the nationally representative National Vietnam Veterans Readjustment Study (NVVRS, 1985), showed little improvement and frequent deteriorations of participants with PTSD [3]. Chronic PTSD is associated with poor physical health, inferior well-being, and unemployment [4]. The disorder is often comorbid with mood, anxiety, and substance use disorders [5, 6]. Co-occurring mental disorders worsen affected survivors’ outcome and increase the burden on public health.

Unlike other mental disorders, PTSD follows a distinct triggering event and has a clear onset point. Early PTSD symptoms develop within days of trauma exposure. Many trauma-exposed individuals are brought to the attention of emergency care services and helpers. These conditions create unique opportunities for detecting survivors at risk and providing preventive interventions. Conceptual models of PTSD’s pathogenesis, discussed below, have informed most early prevention techniques [7-9]. Despite these favorable attributes of PTSD, its systematic prevention is elusive at this point, and the
disorder’s prevalence in the last four decades is remarkably stable, in both military personnel and civilians [10, 11].

The reasons that stagnate prevention of PTSD have not been fully elucidated, but several possibilities have been identified. Current preventive interventions were derived from evidence in chronic PTSD and may not properly engage the disorder’s pathogenesis. Efficient interventions have not been implemented on a large scale. Risk detection is imperfect. Service delivery is difficult when hostilities continue (e.g., during wars, mass relocation, protracted abuse). Studies have documented barriers to seeking help among symptomatic survivors. Community resources might not suffice for intense individual interventions.

Nonetheless, a rapidly growing body of work better informs our understanding of post-traumatic psychopathology, its neurobiological mechanisms, the resulting symptom trajectories, and putative trajectory moderators. This review outlines the better-researched theoretical models of PTSD and related interventions and discusses directions for future research and individual-specific prevention.

**Theoretical Models and Intervention Targets**

**Interventions’ Taxonomy**

Individuals’ reactions to traumatic events follow diverging trajectories. From quasi-universal disarray and distress, shortly after exposure, some survivors develop very few symptoms; others show transient and reversible initial symptoms, and a substantial minority keeps expressing severe non-remitting symptoms [12-14]. These findings define two primary goals for early interventions: Firstly, to mitigate the development of early symptoms, and secondly, to increase the likelihood of remission in those who develop symptoms (with special focus on the non-remitting subgroup). Interventions addressing the first goal include attempts to reduce the stressfulness of the traumatic event (e.g., ‘stress management,’ ‘need-based assistance’) [15, 16], and interventions meant to reduce participants’ initial responses to the event or its encoding in memory. Studies addressing the second goal include specific intervention protocols delivered at different time intervals from the traumatic event to survivors identified as being at high risk for PTSD. The efficacy of the latter, therefore, hinges on proper risk detection at the early aftermath of trauma exposure. Individual risk prediction, however, is currently far from perfect.

**Promise and Current Limitations of Individual Risk Prediction**

Empirically identified risk factors for PTSD are abundant. These can be temporally classified into pre-exposure ‘vulnerability’ factors, peri-traumatic factors and reactions directly related to the event, and post-exposure adversities. Pre-existing vulnerability factors range from neurobiological factors, such as genetic endowment and epigenetic regulation, through environmental factors, such as prior trauma exposure, family and personal psychiatric history, lower education, and stressful, resourceless living conditions, to behavioral factors, such as impaired executive function and higher emotional reactivity [17, 18]. Peri-traumatic factors include trauma intensity and type (e.g., intentional vs. unintentional), peri-traumatic symptoms, physiological arousal (e.g., heart rate) and gene expression. Post-exposure factors encompass social support (a protective factor), and ‘secondary’ stressors (e.g. unemployment as a result of the event) [19, 20].

Despite such an abundance of potential risk indicators, this knowledge has not yet been translated into individual risk prediction. One shortcoming of research to date is the use of statistical modeling that does not properly account for within-group heterogeneities. Studies universally use central tendency statistics, thereby implying that groups studied (e.g., rape victims, accident victims) are inherently homogeneous. However, trauma-exposed individuals are inherently heterogeneous, each bringing to the event his or her own array of vulnerability factors, environmental pressures (and provisions), psychological outfit and subjective appraisal of the traumatic event. Recent studies have used advanced analytic methods to define within - individual (as opposed to group average) symptom trajectories as the outcome of interest, and used machine-learning algorithms to make risk predictions. Several interchangeable sets of early risk indicators have been described including combinations of initial distress, early symptoms, injury severity, head injury, and subjective need for help [21, 22], allowing more versatile individual prediction. Current studies are exploring the clinical utility of such algorithmic solutions for calculating individual risk and predicting the need for intervention.

**Theory-Driven Interventions**

Most preventive studies to date are theory-informed. Figure 1 presents the main theoretical models of PTSD pathogenesis, linking each model with specific interventions. The figure posits a progression from genetics and epigenetic vulnerability factors, childhood experience to peri-traumatic distress, and to specific pathogenic mechanisms operating during trauma exposure and its aftermath. The latter include psychological (appraisal of trauma, recovery environment) and putative neurobiological mechanisms underlying the pathogenesis of PTSD. The current review will only focus on secondary and tertiary prevention, which target the progression of psychopathology after the traumatic event. Interventions targeting elements in that progression (e.g., fear conditioning, emotion processing, initial neuroendocrine response) are associated with each element [23]. Considering such a progression shows that
Interventions’ timing and window of opportunity may be crucial for affecting relevant pathogenic mechanisms. For example, trauma memories may consolidate within hours of trauma, or during the first night sleep such that interventions designed to disrupt initial memory consolidation (pharmacological or psychological) must be provided within such timeframe [24, 25]. Other mechanisms in posttraumatic psychopathology, such as changes in memory, context processing, and nociceptive circuits may also occur within a currently unmapped timeframe, calling for time-dependent intervention delivery [26].

Overview of Preventive Interventions

Psychological or Behavioral Interventions

The Demise of Psychological Debriefing

Psychological debriefing was a widely used method in the 1980s–1990s which aimed at preventing long-term post-traumatic symptoms by promoting quick emotional processing of traumatic events shortly after trauma exposure [27]. Debriefing was offered to survivors of a potentially traumatic event without prior diagnosis or evaluation, exposure being considered as good-enough risk indicator. The method typically involved a single session within hours or a few days after trauma exposure, either in a group or individual, and included general education about trauma exposure and its effect, sharing and validation of individuals’ experiences, and preparation for future encounters [28]. The method has face validity and is still well-known and, therefore, may be expected by lay people when confronted with traumatic events. However, well-conducted studies showed no evidence of beneficial effects and even suggested that debriefing may have a negative effect on recovery [29-31]. After a negative Cochrane review was first published in 1997, most treatment guidelines have been updated to recommend against providing single session psychological debriefing on a routine basis for adults after trauma [32, 33].

Cognitive Behavioral Therapy (CBT)

Trauma-focused CBT can involve different strategies with distinct aims. Exposure-based CBT, exemplified by the prolonged exposure (PE) protocol [34], aims to achieve and maintain fear extinction through repeated exposure to trauma-related stimuli in a safe context, thereby providing a sense of control over reactions and reducing avoidance. Cognitive-based CBT challenges the patient’s beliefs about the meaning and current implication of the trauma. It does so in order to change the way patients react to trauma-related reminders, to remove behavioral restrictions and rules derived from the
traumatic experiences, and to reduce negative appraisal of self and others. CBT is offered individually or in a small group, to people who report symptoms (otherwise there are no ‘intervention targets’), and typically involves several weekly sessions, homework, and in vivo training exercises. The treatment may continue for over 3 months and requires significant skills from the therapists.

Trials of exposure-based CBT have generally demonstrated moderately positive results in reducing PTSD or other symptoms in the long term (Table 1). Rothbaum et al. (2012) conducted a study using modified Prolonged Exposure (PE) in rape, assault, and motor vehicle accidents survivors around 12 h after trauma, and found lower PTSD symptoms in the intervention group at 4 and 12 weeks after trauma, mainly for sexual assault victims. The same cohort also showed that PE might mitigate symptoms of PTSD in genetically predisposed individuals [35, 36•]. Bryant et al. (2008) found 5 weeks of exposure-based CBT to be effective in reducing PTSD in participants who met acute stress disorder diagnostic criteria [37]. Bisson et al. (2004) found a reduction of PTSD symptoms at 13 months—but not 3 months after the traumatic events [38], while a small study with 3 weeks of PE did not find significant symptom improvement in the PE group compared to supportive counseling [39].

CBT without in-session exposure has shown effectiveness in some but not all studies. Sijbrandij et al. (2007) compared CBT to waitlist control subjects with acute PTSD and found that CBT accelerated recovery, but makes no long-term difference [40]. Shalev et al. (2012), found that cognitive therapy fared as well as prolonged exposure 9 months [41•] after trauma exposure. However, neither intervention separated from non-intervention at 3 years [42]. Individuals classified as non-remitting [14] in that cohort were also treatment refractory.

Modifications of clinician-administered CBT, meant to make treatment more affordable or accessible, showed varied results. Irvine et al. (2011) conducted a telephone-based CBT in patients with an implantable cardioverter defibrillator installed and reported significant improvements in PTSD symptoms in the CBT group [43]. Mouthaan et al. (2013) developed a self-guided internet-based intervention (Trauma TIPS) based on CBT to prevent the onset of PTSD symptoms. The result did not support the efficacy of Trauma TIPS [44]. Two negative studies of five sessions of early telephone-based CBT have recently been submitted for publication (O’Donnell ML, Shalev AY personal communication).

CBT is currently the mainstay of early prevention of PTSD. Several considerations, however, make its systematic implementation a major challenge. First, CBT might not be needed in a large proportion of symptomatic survivors. A meta-analysis of early interventions has indicated that CBT is only efficient in participants with diagnosable PTSD at treatment onset [45, 46], and results from the Jerusalem Trauma Outreach and Prevention Study (J-TOPS) have similarly shown that survivors with sub-threshold PTSD symptoms equally recover with or without CBT [41•]. A study by Rothbaum et al. [36•] suggests that efficacy of early CBT is strongly dependent on the type of traumatic event. CBT was most effective for sexual assault victims, had a marginal effect among accident victims, and was not effective for victims of physical assault. Additionally, CBT was found to equally reduce chronic PTSD symptoms when delivered 1 or 5 months after the traumatic event [41•] and its initial effect was conserved for 3 years [42].

CBT is consequently best positioned as a clinical intervention for identified and ascertained acute PTSD cases. It is optimally provided at some distance from the traumatic event, during which time survivors with transient symptoms recover. Survivors who recover with early CBT seldom relapse spontaneously but could remain sensitive to subsequent exposure. Importantly, early CBT leaves numerous survivors unimproved (e.g., 20 % of those treated in the J-TOPS) and thus should be supplemented by ‘second-step’ interventions, which unfortunately are very poorly mapped, if at all. CBT is therefore a ‘must try’ in symptomatic trauma survivors, for many of whom it may shorten symptom duration by months and years.

Pharmacological Interventions

Various pharmacological agents have been examined in the prevention of post-traumatic symptoms (Table 2). A Cochrane review in 2014 concluded that in general, there is moderate quality evidence for the efficacy of hydrocortisone, and no evidence for propranolol, escitalopram, temazepam, and gabapentin [47]. This field is rapidly developing as the neurobiological process underlying start to be clarified by more studies.

Hydrocortisone

Hydrocortisone has been shown to be effective especially in patients who have never been treated for psychiatric disorders [48•]. A study recruited 64 trauma survivors in a level I trauma center and randomly assigned them to hydrocortisone and placebo group. At 3 months post trauma, no (0 %) hydrocortisone recipient and 3 (14 %) placebo recipients met full PTSD diagnostic criteria. PTSD symptom severity decreased over time in both groups, with hydrocortisone recipients reporting lower Clinician-Administered PTSD Scale (CAPS) scores than the placebo group (19.4 ± 4 vs.31.3 ± 3) [48•]. The underlying mechanism has not yet been established. One hypothesis is that hydrocortisone can facilitate extinction learning through both non-genomic and genomic effects [49]. Some also believe that high-dose exogenous hydrocortisone administered shortly after trauma may promote recovery through enhancing synaptic plasticity and connectivity. An animal model showed significantly increased dendritic growth and
| Study                  | Design: groups (n) | Population                                      | Interventions starting time* | Treatment sessions/duration | Assessment time points* | Outcome measures                              | Results                                                                 |
|-----------------------|--------------------|-------------------------------------------------|------------------------------|-----------------------------|------------------------|-----------------------------------------------|-------------------------------------------------------------------------|
| Bryant et al. 1998 [50] | Exposure based CBT (12) SC (12) | MVA, industrial accidents survivors with ASD | <2 weeks                     | <2 weeks, 2 and 6 months   | CIDI, IES, BDI, STAI | Fewer PTSD cases, and intrusive, avoidance, and depressive symptoms in CBT group at follow-ups |
| Bryant et al. 1999 [51] | PE (14), PE + anxiety management (15) SC (16) | MVA, non-sexual assault survivors with ASD | <2 weeks                     | <2 weeks, 2 and 6 months   | CAPS-2; IES, BDI, STAI | Fewer PTSD cases in PE and PE + anxiety management groups at follow-ups |
| Ehlers et al. 2003 [52] | CT (28), self-help (28), repeated assessment (29) | MVA Meeting PTSD diagnosis, PDS ≥ 20 | Around 3 months, <6 months | Up to 12 weekly sessions, 1st session 90 min, afterwards 60 min | CAPS, BDI, disability report | Fewer PTSD cases, less PTSD, depression, anxiety symptoms, and reduced disability in CT group at follow-ups |
| Bisson et al. 2004 [38] | Exposure based CBT (76) Standard care (76) | Physical injury, meet PTSD criteria on PDS, HADS >15, or IES >35 | 5–10 weeks                  | 1–3 weeks, 12 weeks, 13 weeks | CAPS, IES | Fewer PTSD symptoms, similar PTSD cases in CBT group at follow-ups |
| Bryant et al. 2006 [53] | Exposure based CBT (33) CBT + hypnosis (30) SC (24) | MVA, non-sexual assault survivors with ASD | <2 weeks                     | 6 weekly sessions, Pre-treatment, Post-treatment, 6 months and 3 years | CAPS, IES, BDI, STAI | Fewer PTSD cases in CBT and CBT + hypnosis groups at follow-ups |
| Foa et al. 2006 [54] | Brief CBT (31) Assessment alone (30) SC (29) | Female victims of assaults, meet symptom criteria for PTSD | 1 month                      | 4 weekly 2-h sessions, Pre-treatment, post-treatment, 9 and 9 months | SCID, PSS, BDI, BAI, SAI | Greater decreases in PTSD severity in CT group after treatment and at 3 months. No group difference at 9 months. |
| Sijbrandij et al. 2007 [40] | Brief CBT (79) Waitlist Control (64) | Assault, accidents, witness, etc. Meeting acute PTSD | <3 months                    | 4 weekly 120-min sessions, Pre-treatment, 1 week and 4 months after treatment | SCID | Accelerated recovery in the CBT group after treatment; no difference in long-term outcome |
| Bryant et al. 2008 [37] | Exposure based CBT (30), Cognitive restructuring (30) Waitlist (30), PE (19), SC (21) | MVA, non-sexual assault, preliminary diagnosis of ASD | <1 month                      | 5 weekly 90-min sessions, Pre-treatment, post-treatment, 6 months | CAPS, BDI, BAI, PTCI | Fewer PTSD in CBT group, not in cognitive restructuring group at follow-ups |
| Freyf et al. 2010 [39] | PE (19), SC (21) | Accident, assault victims, with ASD diagnosis | 21 days                      | 3 weekly sessions (90, 60, 60 min), Pre-treatment, 1 week after treatment, 3 months, 4 years (telephone) | IES-R, DQ, PTCI, STAI, BDI | No significant group difference in symptomatic improvement. |
| Irvine et al. 2011 [43] | CBT (96) Usual care (97) | Cardioverter defibrillator patients | <2 months                    | 8 weekly telephone-based counseling sessions, Before hospital discharge, 6 and 12 months | HADS, IES-R, Crown-Crisp Experiential Summary, SF-36 | Significant PTSD symptom improvements in CBT group at follow-ups |
| Shalev et al. 2012 [41] | PE (63), CT (40), Escitalopram (23), placebo (23) Waiting List/ Delayed PE (93) | ER trauma survivors, PTSD diagnosis (without duration criteria) | 20 days                      | 12 weeks, 9 days, 20 days, 5 months, 9 months | CAPS, SCID, PSS-SR | Lower 5-month prevalence of PTSD in PE and CT. No 9-month difference between early and delayed PE |
| Rothbaum et al. 2012 [36] | Modified PE (69) Assessment only (n = 68) | Rape, assault, MVA, meet Criterion A | 12 hours                     | 3 weekly 60-min sessions | PSS-I, BDI, PDS | Lower PTSD symptoms at follow-ups, especially in sexual assault victims |
### Table 1 (continued)

| Study | Design: groups \( (n) \) | Population | Intervention starting time* | Treatment sessions/ duration | Assessment time points* | Outcome measures | Results |
|-------|--------------------------|------------|-----------------------------|----------------------------|------------------------|-----------------|--------|
| Brunet et al. 2013 [55] | Dyadic CBT (37), control (37) | MVA, other accidents, physical assault, meet Criterion A1 and A2 | About 25 days | 2 sessions, 2 weeks apart | Pre-treatment (21 days), mid-treatment (35 days), post-treatment (3 months) | IES-R, CAPS, SCS, SAS-SR | Less PTSD symptoms in dyadic CBT group post-treatment |
| Shaw et al. 2014 [56] | TF-CBT 6 session \((33)\), TF-CBT \((29)\), comparison (1-session education) \((45)\) | Mothers of premature infants, above clinical threshold in any one of BAL BDI and SASRQ | 2 weeks | 6 or 9 sessions, 1–2 sessions/week, 45–55 min/session | 1–2 weeks after childbirth, 4.5 weeks, 6/7 weeks \((\text{for 9-session TF-CBT group})\) and 6 months | DTS, SASRQ, BDI-II, BAL MINI | Significantly fewer PTSD, anxiety and depression symptoms in CBT group at follow-ups. No difference in effect size between 6- and 9-session interventions. |

ASD acute stress disorder, BAI Beck anxiety inventory, BDI Beck depression inventory, CAPS clinician administered PTSD scale, CBT Cognitive behavioral therapy, CIDI composite international diagnostic interview, CT cognitive therapy, DQ dissociation questionnaire, DTS Davidson trauma scale, ER emergency room, HADS hospital anxiety and depression scale, IES impact of event scale – revised, MINI mini international neuropsychiatric interview, MVA motor vehicle accident, PTSD posttraumatic diagnostic scale, \( \text{PSS-1} \) PTSD symptom scale – interview; \( \text{PSS-SR} \) PTSD symptom scale – self-report, \( \text{PTCI} \) post-traumatic cognitions inventory, PTSD post-traumatic stress disorder, \( \text{SAS-SR} \) social adjustment scale – self-report, SASRQ stanford acute stress reaction questionnaire, SC support counseling, SCID structured clinical interview for DSM disorders, SCS social constrains scale, SF-36 short form \((36)\) Health Survey, STAI state-trait anxiety inventory, TF-CBT trauma-focused cognitive behavioral therapy. *Time indicators (e.g., 4 week, 3 months) are based on time from traumatic events if not specified.

Benzodiazepines are gamma-aminobutyric acid agonists and interact with brain benzodiazepine receptors to enhance inhibitory neurotransmission in many areas of the brain. They are used as tranquilizers and sleep inducers—also interfering with traumatic learning. They were positioned as capable of reducing excessive physiological responses to trauma reminders (via mental imagery) and its lack of effect on PTSD symptoms might be interpreted as suggesting that the acquisition of traumatic memories in PTSD is not limited to amygdala-mediated threat conditioning and involves other modes of learning and memory. Propranolol is a beta-adrenergic antagonist that crosses the blood-brain barrier and, therefore, capable of reducing central nervous system adrenergic drive associated with defensive threat responses. Experimental studies of propranolol exposure to potentially traumatic narratives reduced the recollection of stressful elements of the narrative without affecting traumatic recall in PTSD. Early treatment with propranolol in reducing physiological responses to mental images of traumatic events 3 months after the event — propranolol in reducing physiological responses to mental images of trauma is likely to have PTSD at 6 months [65], a result which was replicated in another sample [65]. A prospective case-control study of 13 trauma survivors treated with the benzodiazepines clonazepam or alprazolam and 13 control cases matched by gender and symptom severity in rodents similarly found that administering diazepam shortly after traumatic events effectively reduced expression of stress hormones [59]. It therefore has to be started soon after the traumatic event thereby enhancing inhibitory transmission in many areas of the brain. They are used as tranquilizers and sleep inducers. Benzodiazepines are gamma-aminobutyric acid agonists and interact with brain benzodiazepine receptors to enhance inhibitory neurotransmission in many areas of the brain. They are used as tranquilizers and sleep inducers—also interfering with traumatic learning. They were positioned as capable of reducing excessive physiological responses to trauma reminders (via mental imagery) and its lack of effect on PTSD symptoms might be interpreted as suggesting that the acquisition of traumatic memories in PTSD is not limited to amygdala-mediated threat conditioning and involves other modes of learning and memory.

Propranolol is a beta-adrenergic antagonist that crosses the blood-brain barrier and, therefore, capable of reducing central nervous system adrenergic drive associated with defensive threat responses. Experimental studies of propranolol exposure to potentially traumatic narratives reduced the recollection of stressful elements of the narrative without affecting traumatic recall in PTSD. Early treatment with propranolol in reducing physiological responses to mental images of traumatic events — propranolol in reducing physiological responses to mental images of trauma is likely to have PTSD at 6 months [65], a result which was replicated in another sample [65]. A prospective case-control study of 13 trauma survivors treated with the benzodiazepines clonazepam or alprazolam and 13 control cases matched by gender and symptom severity in rodents similarly found that administering diazepam shortly after traumatic events effectively reduced expression of stress hormones [59]. It therefore has to be started soon after the traumatic event thereby enhancing inhibitory transmission in many areas of the brain. They are used as tranquilizers and sleep inducers. Benzodiazepines are gamma-aminobutyric acid agonists and interact with brain benzodiazepine receptors to enhance inhibitory neurotransmission in many areas of the brain. They are used as tranquilizers and sleep inducers—also interfering with traumatic learning. They were positioned as capable of reducing excessive physiological responses to trauma reminders (via mental imagery) and its lack of effect on PTSD symptoms might be interpreted as suggesting that the acquisition of traumatic memories in PTSD is not limited to amygdala-mediated threat conditioning and involves other modes of learning and memory.

Propranolol is a beta-adrenergic antagonist that crosses the blood-brain barrier and, therefore, capable of reducing central nervous system adrenergic drive associated with defensive threat responses. Experimental studies of propranolol exposure to potentially traumatic narratives reduced the recollection of stressful elements of the narrative without affecting traumatic recall in PTSD. Early treatment with propranolol in reducing physiological responses to mental images of traumatic events — propranolol in reducing physiological responses to mental images of trauma is likely to have PTSD at 6 months [65], a result which was replicated in another sample [65]. A prospective case-control study of 13 trauma survivors treated with the benzodiazepines clonazepam or alprazolam and 13 control cases matched by gender and symptom severity in rodents similarly found that administering diazepam shortly after traumatic events effectively reduced expression of stress hormones [59]. It therefore has to be started soon after the traumatic event thereby enhancing inhibitory transmission in many areas of the brain. They are used as tranquilizers and sleep inducers. Benzodiazepines are gamma-aminobutyric acid agonists and interact with brain benzodiazepine receptors to enhance inhibitory neurotransmission in many areas of the brain. They are used as tranquilizers and sleep inducers—also interfering with traumatic learning. They were positioned as capable of reducing excessive physiological responses to trauma reminders (via mental imagery) and its lack of effect on PTSD symptoms might be interpreted as suggesting that the acquisition of traumatic memories in PTSD is not limited to amygdala-mediated threat conditioning and involves other modes of learning and memory.
| Study                        | Design: groups (n) | Population                | Intervention starting time* | Treatment duration | Assessment time points* | Outcome measures                        | Results                                                                 |
|------------------------------|--------------------|---------------------------|----------------------------|--------------------|------------------------|----------------------------------------|------------------------------------------------------------------------|
| Schelling et al. 2001 [66]  | Hydrocortisone 18 mg/kg/h iv (9), control (11) | Septic shock                | During shock phase in hospital | 6 days + 12 days taper | 2+ years (31 months) | SCID traumatic memory PTSD-10        | 11 % PTSD in placebo group, 64 % PTSD in treatment group              |
| Pitman et al. 2002 [60]     | Propranolol 40 mg 4x/day (11); placebo (20)    | ER trauma survivors, meet A1 + A2 criteria | <6 h                      | 10 days + 9 days taper | 1 month, 3 months    | CAPS, psychophysiological imagery procedure | Lower mean of CAPS score, and less physiologic responders in propranolol group during follow-ups |
| Schelling et al. 2004 [67]  | Hydrocortisone 10 mg/h iv (26); control (22)   | High risk inflammation patients after cardiopulmonary bypass | Before surgery           | 24 h + 3 days taper     | 6 months              | Traumatic memory PTSS-10              | Slightly lower symptoms in treatment group at 6 months, weak evidence |
| Stein et al. 2007 [61]      | Propranolol 40 mg 3x/day (17); gabapentin 400 mg 3x/day (14); placebo (17) | Physical injury in trauma center | <48 h                      | 2 days uptitration, 8 days acute treatment, 4 days taper | In hospital, 1, 4, and 8 months | PCL-C, CES-D, ASDS, CIDI            | Neither study drug showed a significant benefit over placebo on depressive or posttraumatic stress symptoms |
| Hoge et al 2012 [62]*       | Propranolol 240 mg/day (22), placebo (21)      | ER trauma survivors, meet A1 + A2 criteria | <12 h                      | 10 days + 9 days taper  | 4 weeks, 12 weeks    | CAPS, SCID                             | CAPS score and PTSD diagnosis no difference                          |
| Shalev et al. 2012 [41]*    | PE (63), CT (40), Escitalopram 20 mg/day (23), placebo (23), waiting list/ delayed PE (93) | ER trauma survivors, PTSD diagnosis (without duration criteria) | 20 days                  | 12 weeks              | 9 days, 20 days, 5 months, 9 months | CAPS, SCID, PSS-SR                                | No difference between escitalopram and placebo groups               |
| Delahanty et al. 2013 [48]* | Hydrocortisone 20 mg 2x/day, oral (31); placebo (33) | Traumatic injury, PDEQ > 27 | <12 h                      | 10 days + 6 days taper  | ER, 1 month, 3 months | CAPS, CES-D, SF-36                    | Lower CAPS, more improvement in depression and quality of life in treatment group at follow-ups |
| Suliman et al. 2015 [68]    | Escitalopram 20 mg/day (12); placebo (17)       | Assault, MVA, witnessing, met intrusion or hyperarousal criteria of ASD | <4 weeks                  | 24 weeks              | <4 weeks, 1, 3, 6, 8, 10 months | CAPS, CGI, MINI, MADRS, VAS-D/A, SDS | No difference between groups                                         |

ASD: acute stress disorder, ASDS: acute stress disorder scale, CAPS: clinician administered PTSD scale, CES-D: Center for Epidemiologic Studies depression scale, CGI: clinical global impression scales, CIDI: Composite International Diagnostic Interview, CT: cognitive therapy, ER: emergency room, iv: intravenously, MADRS: Montgomery Asberg Depression Rating Scale, MINI: Mini International Neuropsychiatric Interview, MVA: motor vehicle accident, PCL-C: PTSD checklist – civilian version, PDEQ: Peritraumatic dissociative experience questionnaire, PE: prolonged exposure, PSS-SR: PTSD symptom scale – self-report, PTSD: post-traumatic stress disorder, PTSS-10: posttraumatic symptom scale, SCID: Structured Clinical Interview for DSM Disorders, SDS: Sheehan Disability Scale, SF-36: Short Form (36) Health Survey, VAS-D/A: Visual Analog Scale for Depression and Anxiety. *Time indicators (e.g., 4 weeks, 3 months) are based on time from traumatic events if not specified.
after predator - odor exposure enhanced the acquisition of long-term fear responses (avoidance of open maze and exaggerated startle) [69]. While the exact mechanism of benzodiazepines’ PTSD-enhancing effect is unknown, it is possible that these compounds interfere with extinction learning, a critical phase in threat-response extinction, particularly when administered hours and days after trauma exposure. Remarkably, current evidence on benzodiazepines’ effect relies on small case series, whereas these compounds are widely used to mitigate acute response to stress. Further evidence is clearly needed, including the use of benzodiazepines to affect traumatic recall within minutes or hours from trauma exposure, that is, within the putative memory consolidation phase.

**Morphine**

Animal studies suggest that morphine can produce retrograde amnesia for contextual conditioned fear, possibly through decreasing cyclic adenosine monophosphate or activating N-methyl-D-aspartate receptors in the hippocampus [70]. Observational studies of hospital patients also suggested a possible beneficial effect of morphine administration within 48 h after trauma exposure to survivors who experience pain, reducing the likelihood of a PTSD outcome [71, 72]. A similar result was reported retrospectively in 696 military personnel with severe combat injury, in which not having PTSD was associated with higher likelihood of having received morphine—as per participants’ medical charts [73]. Given the retrospective nature of most studies, more research is needed to separate a specific effect of morphine from a generic ‘analgesic’ effect. Pain after trauma exposure is a potent predictor of PTSD. It is unclear, therefore, whether morphine has any preventive value in trauma survivors without physical pain.

**Other Approaches**

Oxytocin is involved in emotion stress regulation, social engagement, and attachment. Olff et al. (2010) have suggested that oxytocin may buffer the development of PTSD by reducing fear responses and increasing social functioning [74]. The group is currently conducting a randomized control trial to examine the efficacy of intranasal oxytocin administration in preventing PTSD [75]. Neuropeptide Y (NPY) is another neuroendocrine candidate for intervention. An animal study showed that delivery of NPY to rats’ brains has a pronounced effect on reducing the development of PTSD-like symptoms, possibly through modifying stress-triggered dysregulation of hypothalamic–pituitary–adrenal axis and central noradrenergic activity [76]. Besides hormonal intervention, neural-behavioral trainings are also being developed to change negative emotional processing and enhance neurocognitive function. These trainings have shown positive results in treating anxiety disorders and depression [77-79]. With increasingly strong evidence of impaired emotion regulation and executive functions in PTSD, target-specific paradigms for early interventions will continue to emerge.

**Clinical Prevention in Context**

Studies reviewed above summarize the ‘clinical’ implementation of preventive interventions; that is, the provision of specialized treatment to survivors screened or formally diagnosed within a medical care model. Challenging the restricted setting and medical model, Zatzick et al. (2004, 2013) evaluated a stepped collaborative care model, which introduced care managers to address patients’ unique needs using intervention modalities as required (e.g., components of CBT, Motivation Interview, pharmacotherapy). The care team repeatedly measured patient’s symptoms and adjusted levels of care accordingly. Results showed the feasibility and effectiveness of the method with reduced PTSD symptoms in the intervention group [16, 80]. The need-based, multi-method model can be seen as an alternative to a single clinical intervention. It is likely a valuable component in a stepwise approach to early interventions, in which the ‘heavy artillery’ of full-fledged clinical interventions might be offered to those who fail to respond to earlier, cheaper, less demanding interventions in the need-based approach. By extension, it is generally true that current research has been limited to implementing single protocols and, as such, did not explore a sequential implementation of time-appropriate interventions. Such information should be sought and researched actively.

**Conclusions and Future Directions**

The general picture emerging from this review is that the prevention of PTSD, despite its critical importance, is under-researched and inappropriately explored. Treatment protocols have been implemented regardless of sample heterogeneities and individual vulnerabilities [81], rudimentary theoretical assumptions have been hastily translated to haphazard case series, and randomized clinical trials fell short of informing the overall effectiveness of PTSD in a real world. This might be a typical situation in preliminary ‘proof of concept’ research, when treatment protocols must be rigidly implemented to ensure procedure reliability, and there is no empirical foundation to stratify samples—let alone modify treatment approaches according to needs and
progress. In that sense, studies of the prevention of PTSD have successfully passed a first phase of searching in relative darkness.

Despite these critiques, there are many positive lessons to be learned from the current knowledge base. Taken seriously, they may and should guide better-informed efforts. Such efforts should concern the three tenets of efficient secondary prevention: risk assessment, understanding pathogenesis, and matching intervention techniques. Current research already points in that direction. While trauma-focused CBT received much support [45, 46, 82], it has been implemented without consideration of trauma survivors’ heterogeneity—the latter concerning variation in age, gender, trauma type, genetics and genomics, childhood experience, and recovery environment. Studies to date indicate that more refinement is needed—and possible. TF-CBT was reported to be more effective in victims of traffic accidents [83]; exposure therapy was shown to be more beneficial to sexual assault victims or people with high genetic risk [35, 36]. Currently there is no evidence to support any treatment for trauma survivors already on a recovery trajectory. As Roberts et al. (2009) pointed out: current evidence does not support the routine implementation of any type of psychological intervention to all individuals after trauma [46].

From a risk assessment perspective, PTSD is likely multi-causal, and as such, individuals with differing vulnerabilities and different exposure and post-exposure circumstances may come to express the PTSD symptom complex through individual-specific pathways and be responsive to individual-specific interventions. One way to advance the prevention of PTSD is to better map the variety of paths leading to this condition and map those paths into subsets of trauma exposed individuals. Once such knowledge becomes available, personalized target-specific early interventions might replace generic treatment protocols, which in practice are effective for some but not for all.

Several steps should be taken in future studies. We need to step beyond diagnosis-based screenings and develop more complex accurate methods to predict individual risks of expressing debilitating symptoms and impairment after traumatic events. By enhancing prediction models, intervention studies can take the important step to select the most relevant sample for a more rigorous study design and the best clinical interest. At the same time, researchers need to continue exploring and confirming the underlying mechanisms of post-traumatic pathogenesis and, thereby, suggest new targets for novel interventions. These targeted intervention methods can allow clinicians to focus on both specific populations and specific pathological processes.

Compliance with Ethical Standards

Conflict of Interest Wei Qi, Martin Gevonden, and Arieh Shalev declare that they have no competing interests.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Heron-Delaney M, Kenardy J, Charlton E, Matsuoka Y. A systematic review of predictors of posttraumatic stress disorder (PTSD) for adult road traffic crash survivors. Injury. 2013;44(11):1413–22.
2. Seal KH, Bertenthal D, Miner CR, Sen S, Marmar C. Bringing the war back home: mental health disorders among 103,788 US veterans returning from Iraq and Afghanistan seen at department of veterans affairs facilities. Arch Intern Med. 2007;167(5):476–82.
3. Marmar CR, Schlenger W, Henri-Haeas C, et al. Course of posttraumatic stress disorder 40 years after the Vietnam war: findings from the national Vietnam veterans longitudinal study. JAMA Psychiatry. 2015;72(9):875–81.
4. Zatzick DF, Marmar CR, Weiss DS, et al. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatr. 1997;154(12):1690–5.
5. Gallagher MW, Brown TA. Bayesian analysis of current and lifetime comorbidity rates of mood and anxiety disorders in individuals with posttraumatic stress disorder. J Psychiatr Behav Assess. 2015;37(1):60–6.
6. Galatzer-Levy IR, Nickerson A, Litz BT, Marmar CR. Patterns of lifetime PTSD comorbidity: a latent class analysis. Depress Anxiety. 2013;30(5):489–96.
7. Milad MR, Pitman RK, Ellis CB, et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry. 2009;66(12):1075–82.
8. Norholm SD, Jovanovic T, Olin IW, et al. Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry. 2011;69(6):556–63.
9. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatr. 2007;164(10):1476–88.
10. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048–60.
11. Kilpatrick DG, Resnick HS, Milak M, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26(5):537–47.
12. Bonanno GA, Kennedy P, Galatzer-Levy IR, Lude P, Elfstrom ML. Trajectories of resilience, depression, and anxiety following spinal cord injury. Rehabil Psychol. 2012;57(3):236–47.

13. deRoon-Cassini TA, Mancini AD, Rusch MD, Bonanno GA. Psychopathology and resilience following traumatic injury: a latent growth mixture model analysis. Rehabil Psychol. 2010;55(1):1–11.

14. Galatzer-Levy IR, Anker Y, Freedman S, et al. Early PTSD symptom trajectories: persistence, recovery, and response to treatment: results from the Jerusalem Trauma Outreach and Prevention Study (J-TOPS). PLoS One. 2013;8(8):e70084.

15. Hobfoll SE, Watson P, Bell CC, et al. Five essential elements of immediate and mid-term mass trauma intervention: empirical evidence. Psychiatry. 2007;70(4):283–315.

16. Zatzick D, Jankovich G, Rivara FP, et al. A randomized stepped care intervention trial targeting posttraumatic stress disorder for surgically hospitalized injury survivors. Ann Surg. 2013;257(3):390. This study integrated different intervention methods using stepped care and found that having primarily low intensity treatment embedded in care management could have better population impact.

17. Guthrie RM, Bryant RA. Auditory startle response in firefighters before and after trauma exposure. Am J Psychiatry. 2005;162(2):283–90.

18. Aupperle RL, Melrose AJ, Stein MB, Paulus MP. Executive function and PTSD: disengaging from trauma. Neuropsychopharmacology. 2012;62(2):686–94.

19. Brewin CR, Andrews B, Valentine JD. Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol. 2000;68(5):748.

20. Ozer EJ, Best SR, Lipsey WW, et al. Prospective predictors of post-traumatic stress disorder following the Los Angeles earthquake. Am J Psychiatry. 2003;160(12):2041–7.

21. Galatzer-Levy IR, Karstoft K-I, Statnikov A, Shaley AV. Quantitative forecasting of PTSD from early trauma responses: a machine learning application. J Psychiatr Res. 2014;59:68–76.

22. Karstoft K-I, Galatzer-Levy IR, Statnikov A, Li Z, Shaley AV. Bridging a translational gap: using machine learning to improve the prediction of PTSD. BMC Psychiatry. 2015;15(1):30.

23. Feldner MT, Monson CM, Friedman MJ. A critical analysis of approaches to targeted PTSD prevention current status and theoretically derived future directions. Behav Modif. 2007;31(1):80–116.

24. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits for mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116–24.

25. Myers KM, Ressler KJ, Davis M. Different mechanisms of fear extinction dependent on length of time since fear acquisition. Learn Mem. 2006;13(2):216–23.

26. Walker MP. A refined model of sleep and the time course of memory formation. Behav Brain Sci. 2005;28(01):51–64.

27. Bisson JJ, Deahl MP. Psychological debriefing and prevention of post-traumatic stress. More research is needed. Br J Psychiatry. 1994;165(6):717–20.

28. Bryant RA. Early intervention after trauma. Evidence based treatments for trauma-related psychological disorders: Springer; 2015: 125-142.

29. Rose S, Bisson J, Churchill R, Wessely S. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002;2(2).

30. Van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM. Single session debriefing after psychological trauma: a meta-analysis. Lancet. 2002;360(9335):766–71.

31. Mayou R, Ehlers A, Hobbs M. Psychological debriefing for road traffic accident victims. Br J Psychiatry. 2000;176(6):589–93.

32. Forbes D, Creamer M, Phelps A, et al. Australian guidelines for the treatment of adults with acute stress disorder and post-traumatic stress disorder. Aust N Z J Psychiatry. 2007;41(8):637–48.

33. NICE. The management of PTSD in adults and children in primary and secondary care. National Clinical practice Guideline. 2005.

34. Foa E, Hembree E, Rothbaum BO. Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences therapist guide. Oxford University Press; 2007.

35. Rothbaum BO, Kearns MC, Reiser E, et al. Early intervention following trauma may mitigate genetic risk for PTSD in civilians: a pilot prospective emergency department study. J Clin Psychol. 2014;70(12):1380–7.

36. Rothbaum BO, Kearns MC, Price M, et al. Early intervention may prevent the development of posttraumatic stress disorder: a randomized pilot civilian study with modified prolonged exposure. Biol Psychiatry. 2012;72(11):957–63. First to implement PE within hours of traumatic events and showed effect in specific population. This study emphasized importance of both timeline and high risk population for PTSD prevention.

37. Bryant RA. A randomized controlled trial of exposure therapy and cognitive restructuring for posttraumatic stress disorder. J Consult Clin Psychol. 2008;76(4):695–703.

38. Bisson JJ, Shepherd JP, Joy D, Probert R, Newcombe RG. Early cognitive–behavioural therapy for post-traumatic stress symptoms after physical injury. Br J Psychiatry. 2004;184:63–9.

39. Freyh G, Elsesser K, Lohmann T, Sartory G. Effects of additional prolonged exposure to psychoeducation and relaxation in acute stress disorder. J Anxiety Disord. 2010;24:909–17.

40. Sijbrandij M, et al. Treatment of acute posttraumatic stress disorder with brief cognitive behavioral therapy: a randomized controlled trial. Am J Psychiatry 2007;164(1):82–90.

41. Shaley AV, Anker Y, Israel-Shaley Y, Peleg T, Adessky R, Freedman S. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem trauma outreach and prevention study. Arch Gen Psychiatry. 2012;69(2):166–76. First to compare the preventive effect of SSRI, CT and PE. Results showed no effect of SSRI, similar effects of CT and PE. Delayed PE did not increase the risk of chronic PTSD in the long term.

42. Shaley AV, Anker Y, Gild M, et al. Long-term outcome of early interventions to prevent post-traumatic stress disorder (PTSD). J Clin Psychiatry. accepted.

43. Irvine J, Firestone J, Ong L, et al. A randomized controlled trial of cognitive behavior therapy tailored to psychological adaptation to an implantable cardioverter defibrillator. Psychosom Med. 2011;73:226–33.

44. Mouthaan J, Sijbrandij M, de Vries G-J, et al. Internet-based early intervention to prevent posttraumatic stress disorder in injury patients: randomized controlled trial. J Med Internet Res. 2013;15:e165.

45. Roberts NP, Kitchiner NJ, Kenardy J, Bisson JJ. Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev. 2010;3.

46. Roberts NP, Kitchiner NJ, Kenardy J, Bisson J. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev 2009: CD006869.

47. Amos T, Stein DJ, Ipser JC. Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2014;7:CD006239.

48. Delahanty DL, Gabert-Quillen C, Ostrowski SA, et al. The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial. CNS Spectrom. 2013;18(2):103–11. Shoved promising pilot data for the efficacy of hydrocortisone as secondary prevention of PTSD. Also called for attention to reliably detecting high-risk population.
49. Hruska B, Cullen PK, Delahanty DL. Pharmacological modulation of acute trauma memories to prevent PTSD: considerations from a developmental perspective. Neurobiol Learn Mem. 2014;112:122–9.

50. Bryant RA, et al. Treatment of acute stress disorder: A comparison of cognitive-behavioral therapy and supportive counseling. J Consult Clin Psychol 1998;66:862–866.

51. Bryant RA, et al. Treating acute stress disorder: An evaluation of cognitive behavior therapy and supportive counseling techniques. Am J Psychiatr 1999;156(11):1780–1786.

52. Ehlers A, et al. A randomized controlled trial of cognitive therapy, a self-help booklet, and repeated assessments as early interventions for posttraumatic stress disorder. Arch Gen Psychiatry 2003;60:1024–1032.

53. Bryant RA, et al. Hypnotherapy and cognitive behaviour therapy of acute stress disorder: A 3-year follow-up. Behav Res Ther 2006;44:1331–1335.

54. Foa EB, et al. An evaluation of three brief programs for facilitating recovery after assault. J Trauma Stress 2006;19:29–43.

55. Brunet A, et al. Randomized controlled trial of a brief dyadic cognitive-behavioral intervention designed to prevent PTSD. European Journal of Psychotraumatology. 2013;4. doi:10.3402/ejt.v4i0.21572.

56. Shaw RJ, et al. Prevention of traumatic stress in mothers of preterms: 6-month outcomes. Pediatrics. 2014;134:e481–488.

57. Zohar J, Yahalom H, Kozlovsky N, et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies. Eur Neuropsychopharmacol. 2011;21(11):796–809.

58. Reist C, Duffy JG, Fujimoto K, Cahill L. Pharmacologically driven pharmacologic modulation of acute trauma memories to prevent post-traumatic stress disorder: a systematic review. Am J Psychiatry. 2009;55:627–633.

59. Suliman S, et al. Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial. BMC Psychiatry 2015;15:24.

60. Mata MA, Zohar J, Kaplan Z, Cohen H. Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD. Eur Neuropsychopharmacol. 2009;19(4):283–95.

61. McNally GP, Westbrook RF. Temporally graded, context-specific retrograde amnesia and its alleviation by context preexposure: Effects of postconditioning exposures to morphine in the rat. J Exp Psychol Anim Behav Process. 2003;29(2):130.

62. Mouthaan J, Sijbrandij M, Reitsma JB, et al. The role of early psychopharmacotherapy in the development of posttraumatic stress disorder symptoms after traumatic injury: an observational cohort study in consecutive patients. Gen Hosp Psychiatry. 2015;37:230–5.

63. Bryant RA, Creamer M, O’Donnell M, Silove D, McFarlane AC. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009;65(5):438–40.

64. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010;362(2):110–7.

65. Offit M, Langeland W, Witteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr. 2010;15(8):522–30.

66. Frijling JL, van Zuiden M, Koch SBJ, et al. Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: study protocol of a randomized controlled trial. BMC Psychiatry. 2014;14:92.

67. Serova LI, Tillinger A, Alaluf LG, Laukova M, Keegan K, Sabban EL. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience. 2013;236:298–312.

68. Frijling JL, van Zuiden M, Koch SBJ, et al. Efficacy of oxytocin administration early after psychotrauma in preventing the development of PTSD: a systematic review. Depress Anxiety. 2012;29:833–42.

69. Siegle GJ, Ghinassi F, Thase ME. Neurobehavioral therapies in the 21st century: summary of an emerging field and an extended example of cognitive control training for depression. Cogn Ther Res. 2007;31(2):235–62.

70. Taylor CT, Bomyea J, Amir N. Malleability of attentional bias for positive emotional information and anxiety vulnerability. Emotion. 2011;11(1):127.

71. Siegle GJ, Chesebro B, Thase ME. Neurobehavioral therapies in the 21st century: summary of an emerging field and an extended example of cognitive control training for depression. Cogn Ther Res. 2007;31(2):235–62.

72. Zatzick DF, Roy-Byrne P, Russo J, et al. A randomized effectiveness trial of stepped collaborative care for acutely injured trauma survivors. Arch Gen Psychiatry. 2004;61(5):498–506.

73. Kears MC, Ressler KJ, Zatzick DF, Rothbaum BO. Early interventions for PTSD: a review. Depress Anxiety. 2012;29:833–42.

74. Fomeris CA, Garthleher G, Brownley KA, et al. Interventions to prevent post-traumatic stress disorder: a systematic review. Am J Prev Med. 2013;44:635–50.

75. Kiem S, Kröger C. Prevention of chronic PTSD with early cognitive behavioral therapy. A meta-analysis using mixed-effects modeling. Behav Res Ther. 2013;51:753–61.